OptimizeRx Corporation (OPRX) Guidance & Earnings Results
On 2026-08-12 OptimizeRx Corporation reaffirmed guidance: "FY2026 revenue $95M-$100M; adjusted EBITDA…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
OPRXOptimizeRx CorporationFollow OPRX — free
—
Price chart with a free account
- Market cap
- 172.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 12 Aug 26 | Reaffirmed | FY2026 revenue $95M-$100M; adjusted EBITDA $21M-$25M · full year |
| 5 Mar 26 | — | FY2026 revenue $109-114M; FY2026 adjusted EBITDA $21-25M · full year |
| 6 Nov 25 | Raised | FY25 revenue raised to $105-$109M from prior; adjusted EBITDA $16-$19M; FY26 revenue $118-$124M, adjusted EBITDA $19-$22M · full year |
| 7 Aug 25 | Raised | FY25 revenue raised to $104-108M; FY25 adjusted EBITDA raised to $14.5-17.5M · full year |
OptimizeRx Corporation — questions
- What guidance did OptimizeRx Corporation give?
- On 2026-08-12: "FY2026 revenue $95M-$100M; adjusted EBITDA $21M-$25M"
- When does OptimizeRx Corporation report earnings?
- OptimizeRx Corporation's next earnings report is expected on 2026-11-10.
Every figure on this page comes from OptimizeRx Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.